Uncle Sam Just Bet $160 Million That Gene Editing Can Go Custom
ARPA-H just handed $160 million to seven teams tasked with turning custom gene editing from a $4 million luxury into a scalable platform. The targets: rare childhood diseases. The timeline: patients dosed within three years.
A single baby changed everything.
Sometime in the last couple of years, doctors at the Children's Hospital of Philadelphia used a custom-built CRISPR therapy to treat an infant named KJ, who had a devastating metabolic disorder called CPS1 deficiency. It was a one-patient, one-therapy, one-shot deal. And it worked well enough to spark a much bigger question: what if we could do this for thousands of rare diseases, not just one?
Now the federal government is putting serious money behind that question. ARPA-H, the Pentagon-style research agency but for health, just launched a $160 million, five-year program called THRIVE (Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines). Its mission is audacious: build reusable gene-editing platforms that can crank out personalized cures for rare childhood diseases the way a software company ships updates.
Seven teams got the call. And the implications reach far beyond rare disease.
The $4 Million Problem
To understand why THRIVE matters, you need to understand the ugly economics of gene therapy right now.
The most expensive approved treatment in the U.S. is Lenmeldy, a gene therapy for a rare brain disease. Price tag: $4.25 million per patient. It's not alone in the stratosphere. Hemgenix for hemophilia B runs $3.5 million. Elevidys for Duchenne muscular dystrophy costs $3.2 million. Even Casgevy, the landmark CRISPR-based sickle cell therapy, lists at $2.2 million.
These prices aren't just greed (though there's a debate to be had). They reflect a brutal math problem. Each therapy requires its own manufacturing run, its own quality checks, its own regulatory package. Think of it like commissioning a custom oil painting every time someone needs a new poster. The artistry is incredible, but the process doesn't scale.
For truly personalized therapies (ones designed for a single patient's specific mutation), the economics get even worse. There's no batch production. No economies of scale. Every dose is a bespoke product built from scratch.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
